STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [144] BridgeBio Pharma, Inc. SEC Filing

Family trust tied to BridgeBio (NASDAQ: BBIO) plans new stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) received a notice that the Kumar Haldea Family Irrevocable Trust plans to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares relate to a 03/26/2016 acquisition described as “Conversion Management Incentive Units.” A figure of $2,489,400.00 is listed for these 30,000 shares, and 195,487,474 common shares are shown as outstanding as of 08/19/2026 on NASDAQ. Over the prior three months, related 10b5‑1 sales are reported for Neil Kumar and related trusts, including multiple transactions of 20,000–34,980 shares of BBIO common stock with aggregate proceeds in the low‑ to mid‑million‑dollar range.

Positive

  • None.

Negative

  • None.
Shares to be sold 30,000 shares Common stock covered by the notice for the Kumar Haldea Family Irrevocable Trust
Aggregate value of shares to be sold $2,489,400.00 Amount listed for 30,000 common shares in the securities information section
Shares outstanding 195,487,474 shares BridgeBio common shares shown as outstanding as of 08/19/2026
Neil Kumar 10b5-1 sale 05/21/2026 26,103 shares; $1,812,521.84 Common stock sold under a 10b5-1 plan for Neil Kumar
Neil Kumar 10b5-1 sale 08/18/2026 34,980 shares; $2,886,993.85 Common stock sold under a 10b5-1 plan for Neil Kumar
Haldea Revocable Trust 10b5-1 sale 06/05/2026 20,000 shares; $1,357,538.00 Common stock sold under a 10b5-1 plan for Kumar Haldea Revocable Trust
Haldea Family Irrevocable Trust 10b5-1 sale 06/05/2026 20,000 shares; $1,357,538.00 Common stock sold under a 10b5-1 plan for Kumar Haldea Family Irrevocable Trust
Haldea Family Irrevocable Trust 10b5-1 sale 06/04/2026 20,000 shares; $1,349,106.00 Common stock sold under a 10b5-1 plan for Kumar Haldea Family Irrevocable Trust
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
10b5-1 regulatory
"10b5-1 Sales for NEIL KUMAR 3160 PORTER DRIVE SUITE 250"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Management Incentive Units financial
"Conversion Management Incentive Units | Issuer | | | 30000"
Irrevocable Trust financial
"KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
Revocable Trust financial
"10b5-1 Sales for KUMAR HALDEA REVOCABLE TRUST 3160 PORTER"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

What does this Form 144 filing mean for BridgeBio Pharma, Inc. (BBIO)?
It reports an intended sale of 30,000 BBIO common shares by the Kumar Haldea Family Irrevocable Trust under Rule 144. The notice lists broker details, acquisition background, and recent related 10b5‑1 sales by associated parties.

How many BridgeBio (BBIO) shares are planned to be sold and by whom?
The notice covers 30,000 shares of BridgeBio common stock for the account of the Kumar Haldea Family Irrevocable Trust. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker handling the transaction.

What dollar amount is associated with the 30,000 BBIO shares in this Form 144?
The filing lists an amount of $2,489,400.00 for the 30,000 common shares to be sold. This represents the aggregate value figure disclosed alongside the share amount in the securities information section.

How many BridgeBio (BBIO) shares are shown as outstanding in this notice?
The document shows 195,487,474 BridgeBio common shares as outstanding as of 08/19/2026. This number serves as context for the company’s total common stock compared with the 30,000 shares covered by the notice.

What is the background of the BBIO shares being sold by the trust?
The 30,000 BBIO shares are linked to a 03/26/2016 transaction described as “Conversion Management Incentive Units”. The issuer is listed as the source in that acquisition, indicating the shares originated from a management incentive conversion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR